IP Library Granted Patent US 7,635,569
Granted Patent B2
US 7,635,569 · App. 11/617,191 · Granted Dec 22, 2009

Protein/solubility folding assessed by structural complementation

Assignees: Board of Regents, The University of Texas System; Trustees of Columbia University in the City of New York
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,635,569
App. No.
11/617,191
Granted
Dec 22, 2009
Kind
B2
Abstract

Many proteins, when produced recombinantly, suffer from improper processing, folding and lack normal solubility. Modified proteins, including those indicative of disease states, also can have such defects. The present invention is directed to methods of identifying proper and improper protein folding, aberrant processing and/or insolubility. The method relies on the use of two components: a specialized fusion protein and structural complementation. The fusion protein contains sequences from the protein of interest and one portion of a marker protein that, by itself, is not active. A host cell then provides the remainder of the marker protein that serves to “complement” the function of the fused marker protein such that their association restores activity, permitting detection.

Claims (10)

1. A method for screening a candidate modulator substance for modulation of protein folding and/or solubility comprising:

a) providing an expression construct comprising (i) a gene encoding fusion protein, said fusion protein comprising a protein of interest fused to a first segment of a marker protein, wherein said first segment exhibits only systematic effects on the folding or solubility of the protein of interest, and (ii) a promoter active in said host cell and operably linked to said gene;

b) contacting said fusion protein with a second segment of said marker protein, wherein said second segment is capable of structural complementation with said first segment, wherein contacting takes place in the presence of said candidate modulator substance; and

c) determining structural complementation,

wherein a relative change in structural complementation, as compared to the structural complementation observed in the absence of said candidate modulator substance, indicates that said candidate modulator substance is a modulator of protein folding and/or solubility.

2. The method of claim 1 , wherein said fusion is C-terminal to said protein of interest.

3. The method of claim 1 , wherein said fusion is N-terminal to said protein of interest.

4. The method of claim 1 , wherein said marker protein is selected from the group consisting of a target binding protein, an enzyme, a protein inhibitor, a chromophore.

5. The method of claim 1 , wherein said host cell is selected from the group consisting of a bacterial cell, an insect cell, a yeast cell, a nematode cell, a mammalian cell.

6. The method of claim 1 , wherein said candidate modulator substance is selected from the group consisting of a protein, a nucleic acid or a small molecule.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: HUNT, JOHN F.
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 036790/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2015
From: WIGLEY, WILLIAM CHRISTIAN; STIDHAM, RHESA D.; THOMAS, PHILIP JORDAN
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 036791/0137 →
CONFIRMATORY LICENSE Recorded Jan 11, 2010
From: UNIVERSITY OF TEXAS SW MED CTR/DALLAS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023757/0299 →
Continuity (4)
Continuation 1074872000 · Dec 30, 2003
Division 0977505100 · Jan 31, 2001
Provisional Application 6018228300 · Feb 14, 2000
Related Publication 20070178498A1 · Aug 2, 2007